©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 112249
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.112249
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.112249
Figure 3 The survival rates.
A-C: Across all matched patients, in risk-categorized groups, high-risk group and low-risk group with Barcelona Clinic Liver Cancer (BCLC) stage C disease; D-F: Across all matched patients, in risk-categorized groups, high-risk group and low-risk group with BCLC stage D disease. BCLC: Barcelona Clinic Liver Cancer; BSC: Best supportive care; TACE: Transarterial chemoembolization; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase.
- Citation: Sobnach S, Sousa Silva KC, Abdel-Shafy EAR, Emmamally M, Spearman CW, Bernon M, Sonderup MW, Venter K, Kim I, Kotze U, Segobin R, Creamer DK, Cacciatore S, Zerbini LF, Jonas E. Transarterial chemoembolization outcomes for advanced hepatocellular carcinoma vs sorafenib and best supportive care in a sub-Saharan African cohort. World J Gastroenterol 2025; 31(46): 112249
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/112249.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.112249